The Vancouver, Canada-based biotech firm SaNOtize Research and Development Corporation, which is embarking on Phase III trials for its Nitric Oxide Nasal Spray (NONS) for COVID-19, claims that the self-administered product could potentially hold good against numerous SARS-CoV-2 variants.
Last week, SaNOtize said it had received approval from Health Canada to go-ahead with enrollment of volunteers for the Phase...